Inactive Instrument

Endonovo Therapeutics Inc Share Price OTC Bulletin Board

Equities

US4111551044

Biotechnology & Medical Research

End-of-day quote OTC Bulletin Board
- USD - Intraday chart for Endonovo Therapeutics Inc
Sales 2021 0.07 6.11 Sales 2022 0.14 11.32 Capitalization 34.98L 29Cr
Net income 2021 -30L -25Cr Net income 2022 -1.8Cr -150.52Cr EV / Sales 2021 11,24,21,804 x
Net Debt 2021 70.95L 59Cr Net Debt 2022 71.53L 60Cr EV / Sales 2022 7,86,89,579 x
P/E ratio 2021
-0.3 x
P/E ratio 2022
-0.14 x
Employees -
Yield 2021 *
-
Yield 2022
-
Free-Float 77.47%
More Fundamentals * Assessed data
Endonovo Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Endonovo Therapeutics, Inc 's Sofpulse® Secures Taiwan FDA Approval CI
Endonovo Therapeutics, Inc.'s SofPulse Secures Federal Supply Schedule Inclusion to Accelerate Expansion of VA Distribution CI
Endonovo Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Endonovo Therapeutics, Inc. Announces Pending Agreement to Develop Telehealth Division CI
Endonovo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Endonovo Therapeutics, Inc. Launches SofPulse into the Veterans Administration CI
Endonovo Therapeutics, Inc. Announces Moving Forward in Its Clinical Development in the Field of Traumatic Brain Injury Treatment CI
Endonovo Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Endonovo Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt CI
Endonovo Therapeutics, Inc. Announces Final Stages to Receive Taiwan FDA License to Distribute in Taiwan CI
Endonovo Announces Distribution Agreement with Academy Medical CI
Endonovo Partners with International Distributor for SofPulse Line CI
Endonovo Therapeutics Details Plan to Spin Off Medical Device Division as A Listed Public Company CI
Endonovo Therapeutics, Inc. agreed to Spin-Off Medical Device Division of Endonovo Therapeutics. CI
More news
Managers TitleAgeSince
Chief Executive Officer 59 01/12/01
Investor Relations Contact - 01/14/01
Corporate Officer/Principal 68 01/22/01
Members of the board TitleAgeSince
Chief Executive Officer 59 01/12/01
More insiders
Endonovo Therapeutics, Inc. is a biotechnology company. The Company is focused on developing bioelectronic devices and cell therapies for regenerative medicine and is a commercial-stage developer of non-invasive wearable Electroceuticals therapeutic devices. The Company's portfolio of commercial and clinical-stage wearable Electroceuticals therapeutic devices addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and Central Nervous System (CNS) disorders, including traumatic brain injury (TBI), acute concussions, post- concussion syndrome, and multiple sclerosis. Its non-invasive Electroceutical therapeutic device, SofPulse, uses pulsed short-wave radiofrequency at 27.12 megahertz (MHz) used for the palliative treatment of soft tissue injuries, and post-operative pain and edema, as well as for the treatment of chronic wounds. It offers an alternative, non-opioid treatment through its Electroceuticals systems.
More about the company